Related Experiment Video
Updated: Jul 9, 2026
04:15
A Flow Cytometry-Based High-Throughput Technique for Screening Integrin-Inhibitory Drugs
Published on: February 2, 2024
Natalizumab: targeting alpha4-integrins in multiple sclerosis
Britta Engelhardt1, Ludwig Kappos
1Theodor Kocher Institute, University of Bern, Bern, Switzerland. bengel@tki.unibe.ch
Neuro-Degenerative Diseases
|December 14, 2007
Summary
Natalizumab, an antibody targeting alpha(4)-integrins, effectively treats relapsing-remitting multiple sclerosis (MS) by blocking immune cell entry into the brain. Despite initial safety concerns, its benefits in managing MS are re-evaluated.
Area of Science:
- Neuroimmunology
- Immunology
- Pharmacology
Background:
- Monoclonal antibodies blocking alpha(4)-integrins prevent experimental autoimmune encephalomyelitis, an animal model for multiple sclerosis (MS).
- Alpha(4)beta(1)-integrin mediates immune cell attachment to inflamed brain endothelium in MS models.
- Therapeutic effects were attributed to inhibiting immune cell extravasation and central nervous system inflammation.
Purpose of the Study:
- To review the mechanism of action, clinical trial results, and emerging indications of natalizumab in MS.
- To discuss the risk-benefit balance of natalizumab for relapsing MS.
Main Methods:
- Review of preclinical studies demonstrating the role of alpha(4)-integrins in experimental autoimmune encephalomyelitis.
- Analysis of Phase II and III clinical trial data for natalizumab in relapsing-remitting MS.
- Evaluation of safety data following natalizumab's market withdrawal and re-approval.
Main Results:
- Natalizumab showed significant therapeutic effects in preventing relapses and slowing neurological decline in MS patients.
- Three cases of progressive multifocal leukoencephalopathy (PML) led to its temporary market withdrawal.
- Post-evaluation safety data allowed for re-approval in the US and European Community.
Conclusions:
- Natalizumab represents a targeted therapy for MS by inhibiting leukocyte trafficking.
- Further evaluation is needed to fully understand the risk-benefit profile of natalizumab in relapsing MS.
- The re-entry of natalizumab into the clinic signifies a renewed focus on leukocyte trafficking inhibitors for MS treatment.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:10Integrins
Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:15Activation of Integrins
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.